A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
News|Articles|November 2, 2026
FDA updates in urology: October 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from October 2026.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! This month’s regulatory news spanned several areas of urology, with developments in
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
Advertisement
Advertisement